オオツキ　ヒサオ   OOTSUKI Hisao   大槻　尚男    所属   医学部 医学科（東京女子医科大学病院）    職種   特任講師
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Prognostic Utility of the BCIS-CHIP Score in Imaging-Guided Percutaneous Coronary Intervention.
掲載誌名	正式名：The American journal of cardiology 略　 称：Am J Cardiol ISSNコード：18791913/00029149
掲載区分	国外
巻・号・頁	274,pp.29-35
著者・共著者	Nakata Yuki, Shibahashi Eiji, Otsuki Hisao, Arashi Hiroyuki, Kamishima Kazuho, Jujo Kentaro, Oka Toshiaki, Mori Fumiaki, Tanaka Hiroyuki, Sakamoto Tomohiro, Ishii Yasuhiro, Terajima Yutaka, Fujii Shinya, Takagi Atsushi, Haruta Shiyouji, Yamaguchi Junichi
発行年月	2026/06
概要	A complex high-risk indicated percutaneous coronary intervention (CHIP) score was recently developed from the British Cardiovascular Intervention Society (BCIS) database, and its prognostic value has been reported. However, its utility remains nonvalidated in imaging-guided percutaneous coronary intervention (PCI), which has a favorable prognostic association with CHIP. We investigated the usefulness of the BCIS-CHIP score under imaging-guided PCI. This multicenter prospective observational study included patients who underwent imaging-guided PCI. Patients were evaluated and categorized into 4 groups based on BCIS-CHIP scores (0, 1 to 2, 3 to 4, ≥5), for which we assessed the incidence of 1-year major adverse cardiac or cerebrovascular events (MACCE), including all-cause death, nonfatal myocardial infarction, and nonfatal stroke. Secondary outcomes were individual MACCE components, target vessel revascularization, and heart failure events. In total, 1,218 patients were included. MACCE at 1 year occurred in 1.8%, 3.4%, 7.3%, and 11.7% of patients with BCIS-CHIP scores 0, 1 to 2, 3 to 4, and ≥5, respectively (p <0.001). The incidence of a primary endpoint in groups 3-4 (HR: 4.2, 95% CI: 1.48 to 12.2) and ≥5 (HR: 7.4, 95% CI: 2.59 to 21.37) was significantly higher than those in group 0. The BCIS-CHIP score is useful for predicting cardiovascular events in patients who have undergone imaging-guided PCI and could simplify risk stratification of patients with CHIP.
DOI	10.1016/j.amjcard.2026.06.013
PMID	42336345